No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Overview of the lifting of the restriction on trading of A-shares | March 3rd.
According to Zhito Finance APP, on March 3, a total of 8 listed companies had their restricted shares unlocked, with a total market value of approximately 11.094 billion yuan. The specific details of today's restricted share unlock are as follows: Stock Abbreviation Stock Code Restricted Share Type Number of Unlocking Shares Jiangsu Sainty Corp.,Ltd. 600287 Stock-based Incentive 0.6976 million Arcplus Group Plc 600629 Stock-based Incentive 8.546 million Guangdong Zhongsheng Pharmaceutical 002317 Stock-based Incentive 1.675 million Silvery Dragon Prestressed Materials 603969 Stock-based Incentive 4.3488 million Riyue Heavy Industry 603218 Stock-based Incentive 1.3363 million Longqi Technology
Zhongsheng Pharma's Unit Gets Healthcare Institutions' Nod to Conduct Trial on Weight Drug
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Zhongsheng Ruichuang has obtained the ethical approval for the Phase III clinical trial of the Innovative Drug RAY1225 injection.
On February 27, Gelonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that recently, its holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), has independently developed an innovative type of peptide drug, RAY1225 injection. This drug has received ethical approval from the lead unit, Peking University People's Hospital, and the co-lead unit, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, for its multicenter, randomized, double-blind, placebo-controlled phase III clinical trial (REBUILDING-2) on safety and efficacy in overweight/obese participants, allowing the project to commence.
Zhongsheng Pharma's Unit Gets Nod to Produce Pranoprofen in Japan
Guangdong Zhongsheng Pharmaceutical Subsidiary Receives FDA Approval for Peptide Clinical Trial
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SZSE:002317) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
